📊 IONS Key Takeaways
Is Ionis Pharmaceuticals Inc. (IONS) a Good Investment?
Ionis demonstrates strong revenue growth of 33.8% YoY, indicating market traction; however, severe negative free cash flow of -$814.6M (3.3x annual revenue burn rate) combined with unprofitable operations and high leverage (3.69x debt-to-equity) create unsustainable financial deterioration. The company's ability to fund operations and service debt is increasingly at risk without near-term profitability inflection.
Ionis shows solid top-line growth, but the quality of that growth is weak because it is paired with extremely negative operating margins, large net losses, and deeply negative free cash flow. The balance sheet still has meaningful liquidity, yet high leverage, negative interest coverage, and a thin equity base make the financial profile fragile if cash burn does not improve materially.
Why Buy Ionis Pharmaceuticals Inc. Stock? IONS Key Strengths
- Strong revenue growth of 33.8% YoY showing market demand
- Excellent short-term liquidity with 4.10x current ratio and 4.09x quick ratio
- Substantial asset base of $3.4B indicating established operations and pipeline
- Revenue grew 33.8% year over year, indicating commercial or partnership momentum
- Current ratio of 3.83x and quick ratio of 3.81x suggest near-term liquidity is still solid
- Large asset base provides financial flexibility relative to current operating scale
IONS Stock Risks: Ionis Pharmaceuticals Inc. Investment Risks
- Catastrophic negative free cash flow of -$814.6M annually, burning cash at 3.3x revenue rate
- High financial leverage at 3.69x debt-to-equity with $1.8B long-term debt and limited cash cushion of only $173.4M
- Severe operating losses with -47.7% operating margin and -37.6% net margin, indicating core business is unprofitable
- Operating margin of -187.7% and net margin of -187.6% indicate an unsustainable profitability profile
- Free cash flow of -$320.03M and operating cash flow of -$268.58M show heavy ongoing cash burn
- Debt-to-equity of 3.71x with negative interest coverage and only $489.09M of equity creates significant balance-sheet risk
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Operating margin improvement trajectory toward profitability
- Debt reduction or refinancing activities and cash runway sufficiency
- Operating cash flow and free cash flow burn rate
- Debt load relative to equity and progress toward positive operating margin
Ionis Pharmaceuticals Inc. (IONS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.10x current ratio provides a solid financial cushion.
IONS Profit Margin, ROE & Profitability Analysis
IONS vs Healthcare Sector: How Ionis Pharmaceuticals Inc. Compares
How Ionis Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ionis Pharmaceuticals Inc. Stock Overvalued? IONS Valuation Analysis 2026
Based on fundamental analysis, Ionis Pharmaceuticals Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ionis Pharmaceuticals Inc. Balance Sheet: IONS Debt, Cash & Liquidity
IONS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ionis Pharmaceuticals Inc.'s revenue has declined by 16% over the 5-year period, indicating business contraction. The most recent EPS of $-2.56 indicates the company is currently unprofitable.
IONS Revenue Growth, EPS Growth & YoY Performance
IONS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $131.6M | -$92.5M | $-0.56 |
| Q3 2025 | $133.8M | -$128.6M | $-0.80 |
| Q2 2025 | $225.3M | -$23.4M | $-0.15 |
| Q1 2025 | $119.5M | -$142.8M | $-0.93 |
| Q3 2024 | $133.8M | -$140.5M | $-0.95 |
| Q2 2024 | $188.4M | -$66.3M | $-0.45 |
| Q1 2024 | $119.5M | -$124.3M | $-0.87 |
| Q3 2023 | $144.2M | -$47.0M | $-0.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ionis Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
IONS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ionis Pharmaceuticals Inc. (CIK: 0000874015)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IONS
What is the AI rating for IONS?
Ionis Pharmaceuticals Inc. (IONS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IONS's key strengths?
Claude: Strong revenue growth of 33.8% YoY showing market demand. Excellent short-term liquidity with 4.10x current ratio and 4.09x quick ratio. ChatGPT: Revenue grew 33.8% year over year, indicating commercial or partnership momentum. Current ratio of 3.83x and quick ratio of 3.81x suggest near-term liquidity is still solid.
What are the risks of investing in IONS?
Claude: Catastrophic negative free cash flow of -$814.6M annually, burning cash at 3.3x revenue rate. High financial leverage at 3.69x debt-to-equity with $1.8B long-term debt and limited cash cushion of only $173.4M. ChatGPT: Operating margin of -187.7% and net margin of -187.6% indicate an unsustainable profitability profile. Free cash flow of -$320.03M and operating cash flow of -$268.58M show heavy ongoing cash burn.
What is IONS's revenue and growth?
Ionis Pharmaceuticals Inc. reported revenue of $246.1M.
Does IONS pay dividends?
Ionis Pharmaceuticals Inc. does not currently pay dividends.
Where can I find IONS SEC filings?
Official SEC filings for Ionis Pharmaceuticals Inc. (CIK: 0000874015) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IONS's EPS?
Ionis Pharmaceuticals Inc. has a diluted EPS of $-0.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IONS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Ionis Pharmaceuticals Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IONS stock overvalued or undervalued?
Valuation metrics for IONS: ROE of -18.8% (sector avg: 15%), net margin of -37.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IONS stock in 2026?
Our dual AI analysis gives Ionis Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IONS's free cash flow?
Ionis Pharmaceuticals Inc.'s operating cash flow is $-792.8M, with capital expenditures of $21.8M. FCF margin is -331.0%.
How does IONS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -37.6% (avg: 12%), ROE -18.8% (avg: 15%), current ratio 4.10 (avg: 2).
Is Ionis Pharmaceuticals Inc. carrying too much debt?
IONS has a debt-to-equity ratio of 3.69x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 4.10 suggests adequate short-term liquidity.